Search

Edwards Lifesciences Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

85.64 2.51

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

82.71

Max

85.47

Pagrindiniai rodikliai

By Trading Economics

Pajamos

290M

381M

Pardavimai

92M

1.7B

P/E

Sektoriaus vid.

49.429

64.641

Pelnas, tenkantis vienai akcijai

0.78

Pelno marža

23.092

Darbuotojai

16,000

EBITDA

20M

520M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+22.94% upside

Dividendai

By Acuity

Kitas uždarbis

2026-10-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.1B

48B

Ankstesnė atidarymo kaina

83.13

Ankstesnė uždarymo kaina

85.64

Naujienos nuotaikos

By Acuity

55%

45%

253 / 340 reitingas Healthcare

Edwards Lifesciences Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-28 18:46; UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

2026-07-27 19:41; UTC

Social Media
News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

2026-07-24 18:41; UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

2026-07-23 23:41; UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

2026-07-22 18:46; UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

2026-07-21 21:02; UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

2026-07-20 19:56; UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Akcijų palyginimas

Kainos pokytis

Edwards Lifesciences Corp Prognozė

Kainos tikslas

By TipRanks

22.94% į viršų

12 mėnesių prognozė

Vidutinis 102.88 USD  22.94%

Aukščiausias 110 USD

Žemiausias 85 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Edwards Lifesciences Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

16

Pirkti

3

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

253 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat